Resumed Neutral X

DCPH Deciphera Pharmaceuticals

JP Morgan

$14

Upgrades Neutral Overweight X

DCPH Deciphera Pharmaceuticals

Piper Sandler

$23

Upgrades Hold Buy X

DCPH Deciphera Pharmaceuticals

Stifel

$14 $20

Upgrades Neutral Buy X

DCPH Deciphera Pharmaceuticals

Guggenheim

$22

Initiated Outperform X

DCPH Deciphera Pharmaceuticals

Cowen

$25

Upgrades Mkt Perform Mkt Outperform X

DCPH Deciphera Pharmaceuticals

JMP Securities

$23

Downgrades Overweight Eq Weight X

DCPH Deciphera Pharmaceuticals

Barclays

$50 $11

Downgrades Buy Hold X

DCPH Deciphera Pharmaceuticals

Canaccord Genuity

$72 $12

Downgrades Buy Hold X

DCPH Deciphera Pharmaceuticals

Stifel

$60 $10

Downgrades Buy Hold X

DCPH Deciphera Pharmaceuticals

Truist

$65 $10

Initiated Outperform X

DCPH Deciphera Pharmaceuticals

Credit Suisse

$78

Upgrades Mkt Perform Outperform X

DCPH Deciphera Pharmaceuticals

SVB Leerink

$70

Initiated Buy X

DCPH Deciphera Pharmaceuticals

Deutsche Bank

$42

Upgrades Neutral Buy X

DCPH Deciphera Pharmaceuticals

B. Riley FBR

$27 $34

Initiated Underperform X

DCPH Deciphera Pharmaceuticals

Leerink Partners

Initiated Outperform X

DCPH Deciphera Pharmaceuticals

Raymond James

$47

Initiated Buy X

DCPH Deciphera Pharmaceuticals

SunTrust

Downgrades Buy Neutral X

DCPH Deciphera Pharmaceuticals

B. Riley FBR, Inc.

$43

Initiated Buy X

DCPH Deciphera Pharmaceuticals

B. Riley FBR, Inc.

$43

DCPH  Deciphera Pharmaceuticals, Inc.

Deciphera Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing drugs to improve the lives of cancer patients. Its drug candidate includes DCC-2618, DCC-3014 and Rebastinib. Its proprietary kinase switch control inhibitor platform, inhibit the activation of kinases. DCC-2618, an orally administered kinase switch control inhibitor, for the treatment of gastrointestinal stromal tumors (GIST), advanced systemic mastocytosis (ASM), gliomas, including glioblastoma multiforme (GBM), and other solid tumors driven by pan-KIT or PDGFR alpha. DCC-3014 is an orally administered, potent and highly selective inhibitor of colony stimulating factor receptor 1 (CSF1R). Rebastinib is an orally administered, potent and selective inhibitor of the TIE2 immunokinase. Rebastinib binds potently into the switch pocket of TIE2, stabilizing the inhibitory switch and displacing the activation switch to block TIE2 signaling.